Marginal zinc status does not exacerbate pancreatic carcinogenesis associated with dietary soybean trypsin inhibitor concentrate in rats.
Although the etiology of pancreatic cancer is largely unknown, diet-associated factors may play a role. Male Sprague-Dawley rats (14 d of age) were given a single injection of either saline or azaserine and were weaned (21 d) to diets with either adequate (30 micrograms/g) or low (9 micrograms/g) zinc, with or without 1.0 g/100 g active trypsin inhibitor in the form of soybean trypsin inhibitor concentrate. Experimental diets were fed for 14 wk. Regardless of dietary zinc status, diets with soybean trypsin inhibitor concentrate caused hyperplasia and/or hypertrophy of the pancreas. Pancreatic zinc content was not different among groups. Low dietary zinc levels did not affect total body growth rate or serum zinc concentration. Tibia zinc was also used as an indicator of zinc status. Tibia zinc concentration was lower in rats fed diets low in zinc relative to adequate zinc diets. Azaserine-induced acidophilic foci were larger and more numerous when soybean trypsin inhibitor concentrate was present in the diet regardless of dietary zinc level. Thus, low zinc does not exacerbate the soybean trypsin inhibitor concentrate effects that promote pancreatic cancer.
Ellwood
K C
KC
Division of Science and Applied Technology, Office of Special Nutritionals, Food and Drug Administration, Laurel, MD 20708.
Roebuck
B D
BD
Hathcock
J N
JN
D000818:Animals; D001377:Azaserine / Q000494:pharmacology; D001835:Body Weight / Q000187:drug effects; D004032:Diet; D008297:Male; D009752:Nutritional Status; D009929:Organ Size / Q000187:drug effects; D010190:Pancreatic Neoplasms / Q000209:etiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014361:Trypsin Inhibitors / Q000008:administration & dosage / Q000633:toxicity*; D015032:Zinc / Q000008:administration & dosage* / Q000097:blood
D014361:Trypsin Inhibitors; D001377:Azaserine; D015032:Zinc